PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Alphamab Oncology (9966.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG0330A1013
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$5.05B
Revenue (TTM)HK$218.77M
Gross Profit (TTM)HK$142.99M
EBITDA (TTM)-HK$282.78M
Year RangeHK$3.81 - HK$14.24
Target PriceHK$8.00

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Alphamab Oncology

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Alphamab Oncology, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%0.00%50.00%December2024FebruaryMarchAprilMay
-62.22%
67.13%
9966.HK (Alphamab Oncology)
Benchmark (^GSPC)

S&P 500

Returns By Period

Alphamab Oncology had a return of -23.19% year-to-date (YTD) and -61.36% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-23.19%11.05%
1 month19.72%4.86%
6 months-24.44%17.50%
1 year-61.36%27.37%
5 years (annualized)N/A13.14%
10 years (annualized)N/A10.90%

Monthly Returns

The table below presents the monthly returns of 9966.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-40.51%27.09%-9.76%4.86%-23.19%
202321.11%11.01%-9.23%16.08%-47.71%-6.50%20.19%-4.00%-0.35%33.72%-45.13%5.23%-38.52%
2022-26.62%-7.52%-13.87%1.76%-4.20%4.39%-19.04%21.83%-23.56%-9.67%60.62%22.03%-20.59%
2021-18.30%-1.95%-13.65%26.47%41.50%23.33%-13.48%-6.98%-11.80%-8.84%18.16%-28.42%-16.46%
2020-1.29%27.21%-11.83%9.68%8.59%-2.38%-6.77%-1.55%-8.34%3.17%-2.94%7.25%16.29%
20193.70%3.70%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 9966.HK is 8, indicating that it is in the bottom 8% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of 9966.HK is 88
9966.HK (Alphamab Oncology)
The Sharpe Ratio Rank of 9966.HK is 77Sharpe Ratio Rank
The Sortino Ratio Rank of 9966.HK is 88Sortino Ratio Rank
The Omega Ratio Rank of 9966.HK is 88Omega Ratio Rank
The Calmar Ratio Rank of 9966.HK is 66Calmar Ratio Rank
The Martin Ratio Rank of 9966.HK is 1212Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alphamab Oncology (9966.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


9966.HK
Sharpe ratio
The chart of Sharpe ratio for 9966.HK, currently valued at -0.84, compared to the broader market-2.00-1.000.001.002.003.004.00-0.84
Sortino ratio
The chart of Sortino ratio for 9966.HK, currently valued at -1.21, compared to the broader market-4.00-2.000.002.004.006.00-1.21
Omega ratio
The chart of Omega ratio for 9966.HK, currently valued at 0.84, compared to the broader market0.501.001.502.000.84
Calmar ratio
The chart of Calmar ratio for 9966.HK, currently valued at -0.77, compared to the broader market0.002.004.006.00-0.77
Martin ratio
The chart of Martin ratio for 9966.HK, currently valued at -1.25, compared to the broader market-10.000.0010.0020.0030.00-1.25
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.49, compared to the broader market-2.00-1.000.001.002.003.004.002.49
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.52, compared to the broader market-4.00-2.000.002.004.006.003.52
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.501.001.502.001.43
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 2.03, compared to the broader market0.002.004.006.002.03
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.57, compared to the broader market-10.000.0010.0020.0030.009.57

Sharpe Ratio

The current Alphamab Oncology Sharpe ratio is -0.84. This value is calculated based on the past 12 months of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Alphamab Oncology with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
-0.84
2.45
9966.HK (Alphamab Oncology)
Benchmark (^GSPC)

Dividends

Dividend History


Alphamab Oncology doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-81.62%
-0.32%
9966.HK (Alphamab Oncology)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alphamab Oncology. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alphamab Oncology was 86.09%, occurring on Feb 5, 2024. The portfolio has not yet recovered.

The current Alphamab Oncology drawdown is 81.62%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-86.09%Jul 15, 2021632Feb 5, 2024
-56.75%May 21, 2020226Apr 20, 202123May 24, 2021249
-30.77%Feb 27, 202016Mar 19, 202037May 15, 202053
-22.29%May 25, 20219Jun 4, 202113Jun 24, 202122
-13.51%Dec 17, 201917Jan 13, 202018Feb 10, 202035

Volatility

Volatility Chart

The current Alphamab Oncology volatility is 15.77%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%December2024FebruaryMarchAprilMay
15.77%
3.42%
9966.HK (Alphamab Oncology)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alphamab Oncology over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items